How many insider trades does FilingIQ track for INTI?

FilingIQ tracks 19 Form 4 insider transactions for INTI (Inhibitor Therapeutics, Inc.), covering filings from Dec 2, 2019 onwards. 2 of those were filed in the last 90 days.

Are INTI insiders net buyers or net sellers?

Across the full Form 4 history for INTI, 1 transactions (5%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does INTI insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is INTI in?

Inhibitor Therapeutics, Inc. (INTI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $14.50M.

INTI insider trading

OTC Markets OTCQB Healthcare

Inhibitor Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

5% / 0%

Market cap

$14.50M

About Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies initially for basal cell carcinoma nevus syndrome (BCCNS) cancers by utilizing itraconazole; development of therapies initially for basal cell carcinoma (BCC) cancers; and SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. The company was founded in 1992 and is based in Tampa, Florida.

Company website: inhibitortx.com

INTI insider activity at a glance

FilingIQ has scored 19 insider transactions for INTI since Dec 2, 2019. The most recent filing in our index is dated May 5, 2026.

Across the full history, 1 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on INTI insider trades is 47.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live INTI trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,070

UNITED THERAPEUTICS Corp

APLS 272

Apellis Pharmaceuticals, Inc.

NUVL 218

Nuvalent, Inc.

KYMR 215

Kymera Therapeutics, Inc.

HNGE 194

Hinge Health, Inc.

GH 189

Guardant Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for INTI?: FilingIQ tracks 19 Form 4 insider transactions for INTI (Inhibitor Therapeutics, Inc.), covering filings from Dec 2, 2019 onwards. 2 of those were filed in the last 90 days.
Are INTI insiders net buyers or net sellers?: Across the full Form 4 history for INTI, 1 transactions (5%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does INTI insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is INTI in?: Inhibitor Therapeutics, Inc. (INTI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $14.50M.

Methodology & sources

Every INTI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.